Q (sonnet): <conversation_so_far>
<user>
How does ESR1 mRNA expression differ between PAM50 subtypes in TCGA breast cancer?
</user>

<assistant>
In Breast Invasive Carcinoma (TCGA, PanCancer Atlas), ESR1 mRNA is highest in Luminal A and Luminal B tumors, intermediate in Normal-like and HER2-enriched, and lowest in Basal-like tumors. You can see the distribution here:
[ESR1 expression by subtype](https://www.cbioportal.org/results/plots?cancer_study_list=brca_tcga_pan_can_atlas_2018&gene_list=ESR1)
</assistant>
</conversation_so_far>

Continue this conversation: reply to the user's new message.

<user>
Can you do this with METABRIC instead?
</user>

▶ resolve_and_route
{
 "studyKeywords": [
  "METABRIC",
  "breast"
 ]
}

◀ result
{"success":true,"message":"Found 1 study. Use the metadata to call the appropriate navigation tool(s).","data":{"totalCount":1,"studiesWithMetadata":[{"studyId":"brca_metabric","name":"Breast Cancer (METABRIC, Nature 2012 & Nat Commun 2016)","sampleCount":2509,"studyViewUrl":"https://www.cbioportal.org/study?id=brca_metabric","metadata":{"clinicalAttributeIds":["AGE_AT_DIAGNOSIS","BREAST_SURGERY","CANCER_TYPE","CANCER_TYPE_DETAILED","CELLULARITY","CHEMOTHERAPY","CLAUDIN_SUBTYPE","COHORT","ER_IHC","ER_STATUS","GRADE","HER2_SNP6","HER2_STATUS","HISTOLOGICAL_SUBTYPE","HORMONE_THERAPY","INFERRED_MENOPAUSAL_STATE","INTCLUST","LATERALITY","LYMPH_NODES_EXAMINED_POSITIVE","MUTATION_COUNT","NPI","ONCOTREE_CODE","OS_MONTHS","OS_STATUS","PR_STATUS","RADIO_THERAPY","RFS_MONTHS","RFS_STATUS","SAMPLE_COUNT","SAMPLE_TYPE","SEX","THREEGENE","TMB_NONSYNONYMOUS","TUMOR_SIZE","TUMOR_STAGE","VITAL_STATUS"],"molecularProfileIds":["brca_metabric_cna","brca_metabric_methylation_promoters_rrbs","brca_metabric_mrna","brca_metabric_mrna_median_all_sample_Zscores","brca_metabric_mutations"],"heatmapProfileIds":["brca_metabric_methylation_promoters_rrbs","brca_metabric_mrna_median_all_sample_Zscores"],"availableComparisonTabs":["overlap","clinical","survival","alterations","mutations","mrna","dna_methylation"]}}]}}

═ answer (success)
Note: METABRIC uses the "CLAUDIN_SUBTYPE" attribute rather than a dedicated "PAM50" field — in this dataset it captures the same intrinsic molecular subtypes (Luminal A, Luminal B, HER2-enriched, Basal-like, Normal-like), plus a Claudin-low group.

Here is ESR1 mRNA (microarray z-scores) plotted by subtype in the METABRIC cohort (2,509 samples):

[ESR1 expression by CLAUDIN_SUBTYPE — METABRIC](https://www.cbioportal.org/results/plots?cancer_study_list=brca_metabric&gene_list=ESR1)

Once loaded, set the horizontal/grouping axis to "CLAUDIN_SUBTYPE" (Clinical Data) to reproduce the same subtype comparison as before. You should expect the same general pattern — highest ESR1 in Luminal A/B, lowest in Basal-like — but you can confirm the exact distribution directly in the plot.

If you'd like, I can also pull the underlying group-level counts/medians per subtype instead — just let me know.